Seelos Therapeutics to Participate in Two Investor Conferences

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a biopharmaceutical company focused on central nervous system disorders, is set to participate in two upcoming investor conferences. The Guggenheim Healthcare Talks will occur on November 15-16, featuring 1x1 meetings hosted by CEO Raj Mehra and a fireside chat on November 16 at 2:20 PM ET. Additionally, Seelos will participate in The Benchmark Company 10th Annual Discovery on December 2, where Dr. Mehra will host virtual meetings. These events aim to enhance engagement with investors and provide insights into their advancing clinical pipeline.

NEW YORK, Nov. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day on November 15-16^th and in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2^nd, 2021.

Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day

• Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings virtually on Monday and Tuesday, November 15-16^th
• Yatin Suneja, Senior Biotechnology Analyst at Guggenheim Securities, LLC will host a fireside chat with Dr. Mehra on Tuesday, Nov. 16^th at 2:20pm ET
• For conference and fireside chat registration visit: https://guggenheim-neuro-immuno-conference-2021.videoshowcase.net/login

The Benchmark Company 10^th Annual Discovery One on One Investor Conference

• Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 and small group meetings virtually on Thursday December 2^nd
• For registration and more information email: events@benchmarkcompany.com

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-301413478.html

SOURCE Seelos Therapeutics, Inc.

FAQ

When is Seelos Therapeutics participating in the Guggenheim Healthcare Talks?

Seelos Therapeutics will participate in the Guggenheim Healthcare Talks on November 15-16, 2021.

Who is hosting the fireside chat at the Guggenheim Healthcare Talks for Seelos?

Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, will host a fireside chat on November 16, 2021.

What is the date of The Benchmark Company 10th Annual Discovery Conference for Seelos?

Seelos will participate in The Benchmark Company 10th Annual Discovery on December 2, 2021.

What type of meetings will Seelos Therapeutics conduct at the investor conferences?

Seelos Therapeutics will host 1x1 and small group meetings virtually at both conferences.

How can I register for the Guggenheim Healthcare Talks event?

Registration for the Guggenheim Healthcare Talks can be completed via their event link provided in the press release.